Liraglutide is an analog with 97% homology to human glucagon-like peptide-1 (GLP-1) and acts as a GLP-1 receptor agonist (GLP-1 RA) which is used in combination with diet and exercise in the therapy of type 2 diabetes. It can be used either alone or in amalgamation with another antidiabetic drug. Liraglutide is peptide‐1 (GLP‐1) receptor agonist similar to glucagon. It is commercially available in the brand name of Saxenda® and Victoza®. GLP‐1 is precursor of liraglutide and shares 97% amino acid sequence homology with its parental molecule 9. L‐cells of the gastrointestinal tract secret a polypeptide incretin hormone i.e. GLP‐1 in response to nutrients in the lumen. Global Liraglutide Injection Market was valued at just under USD 4,450 million in 2019 and is expected to reach over USD 6,750 million in 2027, growing at a CAGR of over 9.5% during the forecast period.
By application, global Liraglutide Injection market is segmented into Hypoglycemia, Obesity, Diabetes and Others. In 2019, global Liraglutide Injection market was dominated by diabetes segment with almost 75% share in total revenue generation. It is also expected to be the fastest growing segment over the forecast period and maintain its dominance. World is at present encountering a pandemic of diabetes mellitus. Type 2 diabetes is the condition that prevents body from using insulin the right way. Diabetes can cause genuine unexpected problems including coronary illness, visual deficiency, kidney disappointment, and lower-furthest point removals.
Download Free Sample Report @ https://www.eonmarketresearch.com/sample/77312
Growing prevalence of Type 2 diabetes across globe is primarily driving the market growth. Ecological and way of life change coming about because of industrialization and relocation to metropolitan climate from rustic settings might be mindful to a huge degree, for this pandemic of Type 2 diabetes in across globe. Type 2 diabetes is a disastrous disorder characterized by hyperglycemia as a result of insulin resistance, impaired insulin secretion or both. Increasing demand for Liraglutide injectable medicine to treat diabetes mellitus type 2 is expected to drive the market growth over the forecast period. Moreover, Gestational diabetes in women is creating increased risk of type 2 diabetes in the future. Growing incidence of Gestational diabetes in women is further expected to drive the market growth over the forecast period.
Global Liraglutide Injection market is segmented on the basis of distribution channels such as Hospital Pharmacy, Retail Pharmacy and Others. Hospital pharmacy segment accounted for the largest revenue of over USD 2000 million in the year 2019. Hospital pharmacy is presently driving the conveyance direct fragment in the liraglutide infusion market. High danger of illness movement of pancreatitis with the unwise utilization of liraglutide infusion, makes it basic for the exact administering of medication under the management of an emergency hospital pharmacy specialist. It is normal that soon retail drug store will be exhibiting model market development in the creating locales of the world attributable to the arrangement of modest prescriptions because of the inconvenience of government endowment for fundamental medications.
Severe side effects Associated with Carboplatin are expected to hinder the market growth. Common side effects include inflammation of pancreas (pancreatitis), low blood sugar (hypoglycemia), kidney problems (kidney failure), serious allergic reactions, and gallbladder problems, including gallstones. Other serious side effects include possible thyroid tumors, including cancer, increased heart rate and serious allergic reactions.
North America dominated the global liraglutide injections market with over two third share in total revenue generated in 2019. This strong demand for liraglutide injections in the region can be attributed to increasing awareness regarding obesity, growing healthcare expenditure, increasing geriatric population, increasing lifestyle related diseases, growing incidences of obesity and obesity related diseases. The advanced research and development facilities, and new drug developments by the key players are propelling the demand for improved and cost-effective anti-obesity drugs, thus driving the growth of the global anti-obesity drugs market. Moreover, growing awareness of obesity, there is a sudden rise in concern about being overweight due to which consumers are switching to anti-obesity drugs such as liraglutide injection is further expected to show positive market growth during the forecast period.
Major players in global Liraglutide Injection market include but not limited to Novo Nordisk and Others.
Buy This Premium Report: https://www.eonmarketresearch.com/buy/77312
Liraglutide Injection Market by Application, 2015 – 2027 Volume (K Units) and Revenue (USD Million)
Liraglutide Injection Market by Distribution Channel, 2015 – 2027 Volume (K Units) and Revenue (USD Million)
• Hospital Pharmacy
• Retail Pharmacy
Access Full Report @ https://www.eonmarketresearch.com/liraglutide-injection-market-77312
Liraglutide Injection Market by Region, 2015 – 2027 Volume (K Units) and Revenue (USD Million)
• North America
o United States
• Asia Pacific
o South Korea
o Southeast Asia
• Latin America
• Middle East and Africa
o Saudi Arabia
o South Africa
Liraglutide Injection Market by Company, 2018 – 2019 Volume (K Units) and Revenue (USD Million)
• Novo Nordisk
Do Inquiry Before Purchasing Report Here and Ask For Discount: https://www.eonmarketresearch.com/enquiry/77312
Explore Related Reports:
- Global Optical DTI Imaging Technology Market
- Global Choline Alfoscerate (Alpha GPC) Market
- Global Bovine Ephemeral Fever Vaccines Market
- Global Cartilage Repair Regeneration Market
- Global Melatonin Market
- Global Naltrexone HCL Market
Eon Market Research (EMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers.
Eon Market Research
Phone: +1 703 879 7090